click below
click below
Normal Size Small Size show me how
WEEK 9:
Diabetes and its complications:
| acute complications of diabetes | DKA (T1)/ hypoglycaemia (insulin/ SU use) |
| chronic complications of diabetes (macrovascular) | CVA/ IHD/ PVD |
| chronic complications of diabetes (microvascular) | Eyes (retinopathy) Kidneys (nephropathy) Nerves (neuropathy) |
| diabetes in hospitalised patients - reason for higher costs | Higher Rate of Hospitalisation Longer Stays More Procedures, Medications Chronic Complications More Arteriosclerotic Disease More Infections Complicated Pregnancies |
| diabetic foot disease (neuropathy) | Sensorimotor Autonomic |
| diabetic foot disease (ischaemia) | large vessel and small vessel |
| how to screen for diabetic foot disease | Annually, all patients should have a foot review unless there are known problems Inspection for abnormality 10g monofilament sensation Palpation of foot pulses Examination of footwear |
| who screened for foot care | Low risk Intermediate risk patients Active ulcers or high risk patients with active ulceration Medical/ podiatry/ nursing input Antibiotic policy Vascular surgery links |
| who should be screened for retinal screening | All newly diagnosed patients with Type 2 Diabetes should be referred to the Retinal Screening Program |
| retinal screening includes | Annual digital retinal photography Screeners Referral to ophthalmology if necessary |
| characteristic findings in non proliferative diabetic retinopathy | blot haemorrhages and microaneurysms (saccular dilations of vessel wall) |
| characteristic findings of in proliferative diabetic retinopathy | any neovascularisation present |
| treatment management for proliferative diabetic retinopathy | panretinal laser photocoagulation |
| modifiable risk factors for renal disease | hypertension, albuminuria/proteinuria, dyslipidemia, haemoglobin A1C, smoking, anaemia and CaPO4 |
| non modifiable risk factors for renal disease | age, ethnicity and gender |
| strategies for preventing progressive nephropathy in T2D | Blood pressure control (<130/80) Glycaemic control Low-protein diet smoking |
| diabetic nephropathy | ACE-I ARB Irbesartan (PRIME) Losartan (RENAAL) Valsartan (MARVAL) Renin inhibitors (Aliskiren) |
| aspirin use in secondary prevention | large evidence base |
| aspirin use in primary prevention | Increasing evidence that effect is minimal ?use if multiple risk factors ASCEND trial |